Synthetic LXR agonists elevate LDL in CETP species Pieter H. E. Groot 1 , Nigel J. Pearce 1 , John W. Yates 1 , Claire Stocker 1 , Charles Sauermelch, Christopher P. Doe, Robert N. Willette, Alan Olzinski, Tambra Peters, Denise d'Epagnier 2 , Kathleen O. Morasco 2 , John A. Krawiec, Christine L. Webb, Karpagam Aravindham, Beat Jucker, Mark Burgert 3 , Chun Ma, Joseph P. Marino, Jon L. Collins 4 , Colin H. Macphee, Scott K. Thompson, and Michael Jaye 5 Cardiovascular Center for Excellence in Drug Discovery, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406-0939 USA 5 Corresponding author: tel. 610-270-5239, fax. 610-270-6206 email: michael.c.jaye@gsk.com Running title: Synthetic LXR agonists elevate LDL in CETP species List of Abbreviations: ABCA1, ATP-binding cassette protein A1 ABCG1, ATP-binding cassette protein G1 ABCG5, ATP-binding cassette protein G5 ABCG8, ATP-binding cassette protein G8 Angptl3, Angiopoietin-like 3 Apo, apolipoprotein CETP, cholesteryl ester transfer protein FAS, fatty acid synthase GAPDH, glyceraldehyde-3-phosphate dehydrogenase GLUT4, glucose transporter 4 KO, knockout LDLr, LDL receptor LPL, lipoprotein lipase LXR, liver X receptor PEPCK, phosphoenolpyruvate carboxykinase RCT, reverse cholesterol transport SCD, steroyl coA desaturase SREBP,sterol regulatory element binding protein SEM, Standard error of the mean TE, Tris EDTA 1 by guest, on May 30, 2013 www.jlr.org Downloaded from